Mangoceuticals Reports Unregistered Equity Sale
Ticker: MGRX · Form: 8-K · Filed: Sep 27, 2024 · CIK: 1938046
| Field | Detail |
|---|---|
| Company | Mangoceuticals, INC. (MGRX) |
| Form Type | 8-K |
| Filed Date | Sep 27, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $250,000, $1,100, $0.15 |
| Sentiment | neutral |
Sentiment: neutral
Topics: unregistered-sale, equity-securities, sec-filing
TL;DR
Mangoceuticals filed an 8-K for an unregistered equity sale - details TBD.
AI Summary
On September 26, 2024, MANGOCEUTICALS, INC. reported an unregistered sale of equity securities. The filing does not disclose the specific details of the sale, such as the number of shares, the price, or the parties involved, but it is a required disclosure under SEC regulations.
Why It Matters
This filing indicates a transaction involving the company's stock that was not registered with the SEC, which could have implications for investors regarding transparency and potential dilution.
Risk Assessment
Risk Level: medium — Unregistered sales can sometimes signal financial distress or a need for capital, and lack of immediate detail warrants caution.
Key Players & Entities
- MANGOCEUTICALS, INC. (company) — Registrant
- September 26, 2024 (date) — Date of Earliest Event Reported
- Texas (location) — State of Incorporation
- Dallas (location) — Principal Executive Offices City
FAQ
What type of equity securities were sold?
The filing does not specify the type of equity securities involved in the unregistered sale.
How many shares were sold in this unregistered offering?
The filing does not provide the number of shares sold.
What was the price per share or total consideration for the unregistered sale?
The filing does not disclose the price per share or the total amount of consideration received for the unregistered equity sale.
Who were the purchasers of these unregistered equity securities?
The filing does not identify the parties who purchased the unregistered equity securities.
Why was this sale considered an unregistered sale of equity securities?
The filing states it is an 'Unregistered Sales of Equity Securities' under Item 3.02, indicating the sale did not go through the standard SEC registration process, likely relying on an exemption.
Filing Stats: 982 words · 4 min read · ~3 pages · Grade level 14.2 · Accepted 2024-09-27 16:30:38
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 Par Value Per Share MGRX The Nasdaq
- $250,000 — Additional Fourth Closing Shares ") for $250,000 in connection with a partial closing of
- $1,100 — ck each have an initial stated value of $1,100 per share, and as a result, the effecti
- $0.15 — lder thereof, based on a floor price of $0.15 per share. SIGNATURES Pursuant to t
Filing Documents
- form8-k.htm (8-K) — 41KB
- 0001493152-24-038544.txt ( ) — 216KB
- mgrx-20240926.xsd (EX-101.SCH) — 3KB
- mgrx-20240926_lab.xml (EX-101.LAB) — 33KB
- mgrx-20240926_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MANGOCEUTICALS, INC. Date: September 27, 2024 By: /s/ Jacob D. Cohen Jacob D. Cohen Chief Executive Officer